The BioPharm Brief: Precision, Immunotherapy, Expansion

Today on The BioPharm Brief, we’re covering three key developments shaping the biopharma landscape—from targeted liver disease treatments to next-generation cancer immunotherapies and a surge in U.S. manufacturing investment.

First, Madrigal Pharmaceuticals is expanding its metabolic dysfunction–associated steatohepatitis, or MASH, pipeline through a licensing deal with Arrowhead Pharmaceuticals. The company is adding ARO-PNPLA3, an RNA interference therapy designed for patients with a specific genetic mutation linked to disease progression. This move signals a growing emphasis on precision medicine in MASH, where targeting defined patient subgroups may improve treatment outcomes. Early-stage data suggest reductions in liver fat, but the program remains in phase 1 development.

Next, LTZ Therapeutics has secured $38 million to advance its pipeline of myeloid engager immunotherapies. These therapies are designed to activate myeloid cells—an underutilized component of the immune system—to better attack tumors. The funding will support preclinical and early clinical development, reflecting continued investor interest in novel immuno-oncology approaches beyond traditional T-cell targeting strategies.

Finally, on the manufacturing front, Amgen and Eli Lilly and Company are making significant investments in U.S.-based production. Amgen is expanding biologics manufacturing capacity, while Lilly is committing billions to API production and genetic medicine facilities in Indiana. Together, these moves highlight a broader industry shift toward domestic manufacturing, supply chain resilience, and readiness for more complex therapeutic modalities.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

KEY TAKEAWAYS

• Precision medicine is gaining traction in MASH with genetically targeted therapies
• Myeloid cell engagement represents a new frontier in immuno-oncology
• U.S. manufacturing expansion reflects rising demand for advanced therapies and supply chain control